Search results for "Clostridium difficile infection"

showing 3 items of 3 documents

Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection

2016

C. difficile is a major enteric pathogen with worldwide distribution. Its expansion is associated with broad-spectrum antibiotics which disturb the normal gut microbiome. In this study, the DNA sequencing of highly active bacteria and bacteria opsonized by intestinal secretory immunoglobulin A (SIgA) separated from the whole bacterial community by FACS elucidated how the gut dysbiosis promotes C. difficile infection (CDI). Bacterial groups with inhibitory effects on C. difficile growth, such as Lactobacillales, were mostly inactive in the CDI patients. C. difficile was typical for the bacterial fraction opsonized by SIgA in patients with CDI, while Fusobacterium was characteristic for the S…

0301 basic medicineClostridium Cluster IVmedicine.drug_class030106 microbiologyAntibioticslcsh:QR1-502Microbiologylcsh:MicrobiologyantibioticsMicrobiologyHost-Microbe Biology03 medical and health sciencesClostridium difficile infectionmedicineMicrobiomeMolecular Biology16S rRNA gene sequencinghuman gut microbiomebiologyLactobacillalesdysbiosisClostridium difficilebiology.organism_classificationmedicine.diseaseQR1-502030104 developmental biologyBayesian networksFusobacteriumImmunologysecretory immunoglobulin ADysbiosisBacteriafluorescence-activated cell sortingResearch ArticlemSphere
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Effects of antibiotics and Clostridium difficile infection on the human gut microbiota

2015

El cuerpo humano está poblado por complejas comunidades microbianas (definidas como microbiota)que han colonizado una gran variedad de regiones como la piel, las vías respiratorias, o el tracto gastrointestinal,entre otras. La mayor cantidad de microorganismos y la diversidad más alta se encuentran en el tracto gastrointestinal. La microbiota intestinal participa en una gran variedad de funciones que benefician al hospedador como la digestión de los carbohidratos de la dieta y obtención de energía, la síntesis de vitaminas y amino ácidos esenciales, el desarrollo y homeostasis del sistema inmune, la proliferación y diferenciación del epitelio intestinal y la protección contra patógenos opor…

microbiotaUNESCO::CIENCIAS DE LA VIDAgutmicrobial ecology:CIENCIAS DE LA VIDA [UNESCO]antibioticsclostridium difficile infection
researchProduct